This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Zylet

Valeant Pharmaceuticals International, Inc.

Drug Names(s): loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension

Description: Zylet is a topical anti-inflammatory corticosteroid combination for ophthalmic use. It is comprised of loteprednol etabonate, an ester corticosteroid that blocks the release and action of inflammatory mediators, and tobramycin, which is active against common bacterial eye pathogens.

Deal Structure: Bausch + Lomb and Valeant
In May 2013, Valeant and Bausch + Lomb announced that they have entered into a definitive agreement under which Valeant will acquire Bausch + Lomb for $8.7 billion in cash.

In August 2013, Valeant announced it has completed the acquisition of Bausch + Lomb.


Zylet News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug